Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4
Allison B. Andraski, Sasha A. Singh, Hideyuki Higashi, Lang Ho Lee, Masanori Aikawa, Frank M. Sacks
Allison B. Andraski, Sasha A. Singh, Hideyuki Higashi, Lang Ho Lee, Masanori Aikawa, Frank M. Sacks
View: Text | PDF
Research Article Metabolism

The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4

  • Text
  • PDF
Abstract

Apolipoprotein A4’s (APOA4’s) functions on HDL in humans are not well understood. A unique feature of APOA4 is that it is an intestinal apolipoprotein secreted on HDL and chylomicrons. The goal of this study was to gain a better understanding of the origin and function of APOA4 on HDL by studying its metabolism across 6 HDL sizes. Twelve participants completed a metabolic tracer study. HDL was isolated by APOA1 immunopurification and separated by size. Tracer enrichments for APOA4 and APOA1 were determined by targeted mass spectrometry, and metabolic rates were derived by compartmental modeling. APOA4 metabolism on small HDL (alpha3, prebeta, and very small prebeta) was distinct from that of APOA4 on large HDL (alpha0, 1, 2). APOA4 on small HDL appeared in circulation by 30 minutes and was relatively rapidly catabolized. In contrast, APOA4 on large HDL appeared in circulation later (1–2 hours) and had a much slower catabolism. The unique metabolic profiles of APOA4 on small and large HDL likely indicate that each has a distinct origin and function in humans. This evidence supports the notion that APOA4 on small HDL originates directly from the small intestine while APOA4 on large HDL originates from chylomicron transfer.

Authors

Allison B. Andraski, Sasha A. Singh, Hideyuki Higashi, Lang Ho Lee, Masanori Aikawa, Frank M. Sacks

×

Figure 2

APOA1 and APOA4 levels in plasma, in HDL, and across 6 HDL sizes.

Options: View larger image (or click on image) Download as PowerPoint
APOA1 and APOA4 levels in plasma, in HDL, and across 6 HDL sizes.
Concen...
Concentration (mg/dL) of APOA1 in plasma (A), APOA4 in plasma (B), and APOA4 on APOA1-HDL (C). Percentage of total plasma APOA4 on HDL (D). (A–D) Bars and the number at the base of each graph are the mean (±SD) for the 12 participants. Each circle represents a value per participant. Pool size (mg) of APOA1 (E) and APOA4 (F) and percentage distribution of APOA1 (G) and APOA4 (H) across the 6 HDL sizes in participants 1 to 6. (E–H) Number above or below each HDL size represents the average pool size (E and F) or percentage distribution (G and H) in that size fraction. Bars represent mean (±SD). (I) The molar ratio of APOA4 to APOA1 on each HDL size was calculated using the pool size data in E and F.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts